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Abstract
Background: CD4+ T-cell testing of blood specimens collected in standard EDTA Vacutainer tubes and transported at
ambient temperature, must be completed within 48 hours with the BD FACSCount™ flow cytometer, restricting
specimen collection in remote clinics with no on-site testing and limited specimen transport services. We conducted
a study in Buhera District, Zimbabwe, to assess the stability and accuracy of CD4+ T-cell results of samples collected in
Stabilization Tubes (ST) and stored at ambient temperature for varying time periods.
Methods: Paired EDTA and ST samples were collected from 51 HIV-positive patients aged 18 years and older.
CD4+ T-cell testing was done on arrival in the laboratory (Day 0). ST samples were retested on Days 3, 5, and 7.
Nineteen ST samples were stored for an additional week and retested on Day 14.
Results: There was a strong correlation between absolute CD4+ T-cell counts measured in the EDTA Day 0 reference
sample and Day 7 ST sample (Spearman’s rho: 0.9778; mean difference: −4.9 cells/μL and limits of agreement (LOA):
98.5 and 88.7 cells/μL); and the reference sample and Day 14 ST sample (Spearman’s rho: 0.9632; mean difference
5.1 cells/μL and LOA: −99.6 and 109.8 cells/μL. Using a 350 cells/μL threshold, the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were all 100% on Day 7, and 83.3%, 100%, 100% and 92.9% on Day 14.
Using a 500 cells/μL threshold, the sensitivity, specificity, PPV and NVP were 100%, 88.5%, 88.5% and 100% on Day 7 and
88.9%, 80.0%, 80.0% and 88.9% on Day 14.
Conclusions: CD4 ST can be used and stored up to 7 days as a reliable alternative to standard EDTA tubes in settings
where CD4+ T-cell testing within 48 hours is not feasible. Despite the small sample size, results suggest that ST may be
stored up to 14 days at room temperature for CD4 testing, without compromising accuracy. However, further studies with
larger sample sizes are needed to confirm this preliminary finding.
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Background
Among people with HIV infection, CD4+ T-cell count
is used to determine eligibility for antiretroviral treat-
ment (ART) and to monitor treatment response. The
2013 World Health Organization (WHO) HIV guidelines
recommend that ART be provided to all individuals with
confirmed HIV infection who have CD4+ T-cell cell
counts ≤500 cells/μL, and that individuals with CD4+
T-cell counts ≤350 cells/μL should be given priority to
initiate treatment [1].
In countries without access to routine viral load testing,
WHO guidelines stipulate that CD4+ T-cells be measured
every six months to monitor response to treatment [1]. In
addition to the need of CD4 testing for treatment eligibil-
ity and monitoring response to treatment, CD4+ T-cell
testing is used to guide initiation of co-trimoxazole
prophylaxis in patients with a CD4+ T-cell count ≤200
cells/μL or ≤350 cells/μL to prevent co-infections such
as Pneumocystis carinii, toxoplasmosis and bacterial
infections [2], and the initiation of fluconazole prophylaxis
in patients with a CD4+ T-cell count ≤100 cells/μL to pre-
vent cryptococcal disease [3]. These recommendations
were adopted by the Zimbabwean government as policy
and are contained in the December 2013 Zimbabwean
national guidelines [4].
Access to CD4 testing is dependent on having ad-
equate laboratory capacity, and having the means to
transport specimens from peripheral health centres to a
district or central laboratory [5,6]. The Beckton Dickinson
FACSCount flow cytometer remains one of the most used
CD4 testing technologies in resource-limited settings [7].
However, blood specimens collected in standard EDTA
tubes and transported at ambient temperature must be
completed within 48 hours [8]. Due to this short inter-
val to collect specimens and transport them to the dis-
trict laboratory, patients are often requested to return
to the clinic on specific days of specimen collection
and additional visits to the clinic may lead to high
rates of pre-ART attrition [9,10] or failure to perform
monitoring tests to detect treatment failure.
Although new point-of-care (POC) CD4 testing tech-
nologies have emerged recently, and are considered an
important tool to improve retention in care prior to
treatment initiation [11], costs may hamper widespread
implementation in resource-limited settings [12]. High
throughput laboratory-based CD4 testing will therefore
remain an important component in a tiered approach to
service implementation.
Blood stabilizers that allow for storage of blood specimens
for longer periods of time have been developed previously
[13,14]. The BD Vacutainer® CD4 stabilization tubes (ST)
(Becton-Dickinson Vacutainer Systems, Franklin Lakes, NJ)
enable peripheral blood mononuclear cells (PBMCs) to be
preserved for a longer period than with standard blood
collection tubes, enabling the interval between blood
collection and laboratory testing to be increased with-
out compromising measurement accuracy. According
to the manufacturer’s instructions, blood specimens
collected in BD CD4 ST can be stored at temperatures
up to 37°C for up to three days, and at temperatures
up to 30°C for up to seven days before CD4 testing. Al-
though BD CD4 ST have been commercially available
since 2006 [15] there is only one published study, done
in Uganda, that has documented the performance of
CD4 stabilization tubes under field conditions using
the FACSCount flow cytometer and the anti-CD3 and
anti-CD4 antibodies [16]. This study showed an aver-
age CD4 cell decline of 6 cells/day (95% CI, 3.6 – 9.0
cells/day) over the first 8 days. The rate of decline was
less during the first six days (3 cells/day; 95% CI, 0.5 –
7.4 cells/day) than during the subsequent two days (10
cells/day; 95% CI, 4.6 – 24.9 cells/day) with storage at
ambient temperatures between 25°C and 28°C.
Médecins Sans Frontières (MSF) has been supporting
the HIV/TB programme in Buhera District in Manicaland
Province of Zimbabwe since 2004. The programme pro-
vides ART and management of opportunistic infections
(OIs) in children and adults with HIV infection through
an OI clinic at Murambinda Mission Hospital (MMH)
and 22 decentralised clinics. In Buhera district, a weekly
specimen collection service is provided to the primary
health care clinics that provide decentralised ART. This
enables assessment of eligibility for ART, and monitoring
of response to treatment to be carried out without the
need for the patient to travel to the central hospital. How-
ever if the patient’s follow-up visit does not coincide with
the day that specimens are collected, this necessitates an
additional clinic visit for the patient.
The use of CD4 STs for specimen collection, instead
of EDTA Vacutainer tubes, would decrease the number
of patients needing to return to the clinic for specimen
collection because blood specimens could be collected
on the day of the first consultation and be stored for up
to 7 days before CD4+ T-cell testing in the laboratory.
Given the lack of evidence on the performance of BD
stabilization tubes under field conditions, we conducted
a prospective study to assess the performance of CD4
STs for CD4 measurement under field conditions in
Buhera District in Zimbabwe.
Methods
Study population
Blood samples were obtained from 51 HIV-infected indi-
viduals aged 18 years or older who were having blood
drawn to determine ART eligibility or monitor response
to treatment at any of four MSF-supported primary
healthcare clinics in the rural district of Buhera, in
Manicaland Province in Zimbabwe. Ethics approval for
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the study was obtained from the Medical Research
Council of Zimbabwe and the Médecins Sans Frontières
Ethics Review Board. All study participants provided
written informed consent to participate in the study and
for the collection of a second sample of venous blood in
a CD4 Stabilization Tube, which was used as the alterna-
tive blood collection method.
Laboratory procedures
Sample collection and storage in the clinics
In each clinic, a nurse obtained venous blood samples
from each participant by venipuncture. Venous blood
was collected in a standard 4-ml K2 EDTA Vacutainer
tube, which was used as the reference blood collection
method. A second sample of venous blood was collected
in a 2-ml CD4 Stabilization Tube [BD Vacutainer;
Becton Dickinson Vacutainer Systems, Franklin Lakes,
New Jersey, USA] which was used as the alternative
blood collection method. Tubes were inverted ten times
and were stored in vertical racks and transported at
room temperature (18°C – 25°C) to the nearest district
laboratory within 8 hours of sample collection.
Sample processing, storage and testing in the laboratory
The laboratories processed blood samples within 8 hours of
arrival (Day 0). In each laboratory, an experienced labora-
tory technologist carried out the testing. Absolute CD4+
T-cell counts were determined using the BD FACS-
Count™ flow cytometer (Becton Dickinson, San Jose,
California, USA) and the BD FACSCount™ CD4 Reagent
according to the manufacturer’s instructions. The BD
FACSCount™ CD4 Reagent comprises a single tube which
contains all reagents required for absolute CD4+ T-cell
counts and CD4+ T-cell percentages. The BD FACS-
Count™ CD4 Reagent contains three human fluorochrome-
labeled monoclonal antibodies, namely, CD4 PE, CD14
PE-Cy™5, CD15 PE-Cy5, which bind specifically to lympho-
cyte surface antigens, and a fluorescent nuclear dye binds
to the nucleated blood cells. In addition, the reagent tubes
also contain a known number of fluorescent reference
beads. Briefly, 50 μL of anticoagulated venous blood was
added to the BD FACSCount™ CD4 reagent tubes by re-
verse pipetting using the pre-programmed BD FACS-
Count™ electronic pipette. Reagent tubes were incubated in
the workstation for 30 minutes at room temperature (18°C
to 25°C). After 30 minutes, fixative solution was added and
tubes were then vortexed and analyzed with the BD FACS-
Count™ flow cytometer. The software automatically identi-
fies lymphocyte populations and calculates the CD4 counts
(cells/μL) by comparing cellular events to bead events. At
least 10,000 events (20,000 - 45,000 events for the majority
of samples) were acquired. Results included CD4 counts
and CD4 percentages, and were printed immediately after
samples were run.
Internal quality control (IQC) with BD FACSCount
Control Kit (BD Biosciences) was carried out daily prior
to routine testing, according to standard operating pro-
cedure in order to verify system accuracy and linearity.
EDTA tubes were discarded after completion of testing
on Day 0. ST samples were stored in vertical racks at
room temperature and were retested on Days 3, 5 and 7,
after inverting the tube at least 10 times. In one labora-
tory, 19 ST samples were retested on Day 14. Both labora-
tories were enrolled in the AFREQAS external quality
assurance programme (proficiency testing) provided by
the National Health Laboratory Service (NHLS) in South
Africa. The laboratory technologists who carried out the
testing were blind to the reference sample results.
Statistical analysis
Data was analysed using Stata 11 (StataCorp, College Station,
Texas, USA). ST results at each time-point (index test) were
compared with the EDTA Day 0 result (reference test). Sim-
ple statistics, including minimum, maximum, median, and
interquartile range (IQR) were used to describe the distribu-
tion of test results by specimen type and day of testing. Cor-
relation between the ST sample result and the reference test
result was determined by linear regression, and Spearman’s
rho correlation coefficient. Bland-Altman analysis was used
to assess the difference between EDTA and ST results [17].
The mean difference [ST result – reference result] and the
limits of agreement [mean ±1.96 standard deviations (S.D.)]
were calculated and represented graphically in difference
scatter plots. The non-parametric Wilcoxon signed-rank test
and the paired t-test for continuous data were used to estab-
lish statistical significance of paired comparisons with an
alpha value of 0.05 (two-sided test). Clinical agreement was
assessed by calculating sensitivity, specificity, PPV and NPV
with binomial exact 95% confidence intervals (CIs) using
thresholds of 350 cells/μL and 500 cells/μL.
Results
Patient demographics
From 15 to 28 December 2011, paired venous blood
samples were collected from 51 patients. The character-
istics of the study population are summarized in Table 1.
Participants had a median age of 34 years (IQR: 28 – 45)
and 35 were female (68.6%). Twenty-one individuals
were on WHO stage 1 (40.7%), 22 on stage 2 (43.3%) 5
on stage 3 (10.0%), and 3 on stage 4 (6.0%). CD4 test-
ing was performed to determine ART eligibility in 13
individuals (25.0%) and for monitoring purposes in 38
individuals (75%), and the median CD4+ T cell count
was 507.5 cells/μL (IQR: 271.75 – 744.5).
Comparison of CD4 on ST and EDTA
Twenty-eight sets of samples were sent to the labora-
tory at Birchenough Bridge Hospital (BBH), and the
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remaining 23 sets of samples were sent to the laboratory
at Murambinda Mission Hospital (MMH). One pair of
specimens in which the ST results differed markedly
from the EDTA result was excluded from the analysis.
In the excluded pair of specimens the Day 0 CD4+ T-cell
result was 796 cells/μL in the reference specimen, and
468 cells/μL on the ST specimen. We assumed that
this discrepancy was due to mismatching of specimens
(i.e. comparing specimens from different patients) due
to a labelling error. Due to a transient stock-out of
CD4 reagents in one of the laboratories, only 19 ST
samples were tested on Day 14.
After exclusion of the one pair of samples, the median
CD4+ T-cell count in the reference test (EDTA Day 0)
was 508 cells/μL (IQR: 294 – 733). The median of CD4+
T-cell counts of ST samples were comparable to the me-
dian of the reference test and remained relatively constant
over time and differences were not statistically significant
on Day 7 (p = 0.30) and Day 14 (p = 0.71) (Figure 1A). The
summary statistics for correlation and agreement between
ST and EDTA is shown in Table 2. There was a strong
correlation between absolute CD4+ T-cell counts in the
ST samples and the reference test, with Spearman’s
rho 0.9778 on Day 7, and 0.9632 on Day 14 (Figure 1B
and 1C). Bland-Altman analysis found a mean difference
of −4.9 cells/μL with LOA −98.5 to +88.7 cells/μL on Day
7 (Figure 1D); and a mean difference of 5.1 cells/μL, and
LOA of −99.6 to +109.8 cells/μL on Day 14 (Figure 1E).
The values of the CD4+ T-cell% also remained rela-
tively constant over time and difference was not statisti-
cally significant on Day 7 (p = 0.17) (Figure 2A). There
was a strong correlation between the CD4+ T-cell% in
reference samples and the Day 7 ST samples (Spearman’s
rho 0.9778; Figure 2B). Bland-Altman analysis found a
mean difference of −0.539%, and LOA of −4.6 to +3.5%
(Figure 2C). Due to a transient stock-out of CD4 re-
agents in one of the laboratories, only 19 ST samples
were tested on Day 14. CD4+ T-cell absolute counts
were generated at Day 14 but the BD FACSCount flow
cytometer did not produce CD4% results.
Clinical agreement between CD4 measured on ST and
EDTA
We calculated the agreement between the EDTA at day
0 and ST at day 7 and 14 using two clinically important
cut-off values for CD4+ T cells that is currently used
for initiating ART in Zimbabwe: 350 CD4 cells/μL and
500 CD4 cells/μL. Using a 350 cells/μL threshold, the
sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) were all 100% on
Day 7, and 83.3%, 100%, 100% and 92.9% on Day 14.
Using a 500 cells/μL threshold, the sensitivity, specifi-
city, PPV and NVP were 100%, 88.5%, 88.5% and 100%
on Day 7 and 88.9%, 80.0%, 80.0% and 88.9% on Day 14.
The sensitivity, specificity, PPV, NPV and misclassification
rate are shown in Table 3. Using a threshold of 350 cells/μL,
no ineligible patients would have been started on ART based
on the Day 7 and the Day 14 ST results, and one eligible pa-
tient would have been denied ART based on the Day 14 ST
results. Using a threshold of 500 cells/μL, three ineligible pa-
tients would have been started on ART based on the Day 7
results; two ineligible patients would have been started on
ART based on the Day 14 ST results; and one eligible pa-
tient would have been denied ART based on the Day 14 ST
results.
Discussion and conclusions
Results from this study show that specimens collected
and stored in ST at room temperature are stable for up
to 7 days without compromising the accuracy of absolute
CD4+ T-cell counts or CD4+ T-cell% measurements. The
Day 14 results were similar to the EDTA Day 0 results,
suggesting that it may be possible to store ST specimens
for longer than 7 days at room temperature (18°C to
25°C). However, the Day 14 results should be regarded
as preliminary and interpreted with caution in view of
the limited sample size (n = 19). The slightly better
agreement of CD4 measured on ST on Day 7 can be
seen by the negligible mean bias of −4.89 cells/μL and
narrow 95% CI of mean bias (−18.34 to 8.54 cells/μL)
versus 5.10 cells/μL and wider 95% CI of mean bias
(−20.13 to 30.34 cells/μL) reflecting more variability in
the agreement on Day 14. Using a threshold of 350
CD4 cells/μL we found 100% sensitivity and specificity,
with no clinical misclassification of patients, of CD4
measured on ST on Day 7. The excellent sensitivity
was maintained at a threshold of 500 CD4 cells/μL, but
the specificity slightly dropped to 88.5%, and three pa-
tients (6.1%) would have been put on treatment based on
the ST CD4 result. The slightly higher clinical misclassifi-
cation seen at the 500 CD4 cells/μL threshold may be due
Table 1 Participant characteristics
Characteristic Value
Total patients: N 51
Female: n, (%) 35 (68.6)
Age (years): median, (IQR) 34, (28 – 45)





Reason for testing: n, (%)
ART eligibility 13 (25.0)
ART monitoring 38 (75.0)
CD4+ T cells: median, (IQR) 507.5, (271.75 – 744.5)
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Figure 1 Comparison of CD4 counts measured on ST (index test), at different time intervals, and EDTA at day 0 (reference test).
A: box-and-whisker plots displaying the median and upper and lower quartiles. B and C: scatter plots displaying correlation. D and E: Bland-Altman
plots showing the mean difference (solid line) and 95% lower limits of agreement (dotted lines). Blue vertical dashed lines indicate CD4 T cells
thresholds of 350 cell/μL and 500 cells/μL.
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to the intrinsic higher variability of the CD4 test at higher
CD4 counts, as reported by others [18]. This can also be
observed in the agreement scatter plot (Figure 1D) which
revealed a higher variability, with a downward trend, when
the CD4 count was higher, e.g. ≥500 cells/μL.
Our results corroborate the BD manufacturer’s in-
structions which claim that specimens stored in ST at
room temperature are stable up to 7 days without loss of
accuracy. Our results are in agreement with those from
Shott et al. [16] and Varro et al. [19] in which stability
Table 2 Summary statistics for correlation and agreement between CD4+ T cells in ST samples measured on Day 7 and
Day 14 (index test), and CD4+ T cells in EDTA samples measured on Day 0 (reference test)
Test N Median p-value
(EDTA Day 0)




CD4 ST Day 7 49 480 0.30 0.957 0.977 −4.89 (−18.34 to 8.54) 46.81 −98.52 to 88.72
CD4 ST Day 14 19 500 0.71 0.936 0.963 5.10 (−20.13 to 30.34) 52.35 −99.61 to 109.82
CD4% ST Day 7 46 24.15 0.17 0.936 0.948 −0.53 (−1.14 to 0.06) 2.02 −4.59 to 3.51
Figure 2 Comparison of CD4% measured on ST (index test), at different time intervals, and EDTA at day 0 (reference test). A: box-and-whisker
plots showing the median and upper and lower quartiles. B: scatter plot displaying correlation. C: Bland-Altman plots showing the mean difference
(solid line) and 95% lower limits of agreement (dotted lines).
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of specimens for CD4 testing was determined to be
optimum at Day 6 and Day 5, respectively, at room
temperature (change difference <10%); however, in these
studies blood specimens were not tested after longer pe-
riods of storage. To our knowledge, the stability of blood
specimens stored up to 14 days has not been described
previously.
CD4 ST tubes offer several advantages in the
decentralization of CD4 testing in remote settings.
Firstly, specimen collection for CD4 testing can be
done on the same day that patients attend the health
facility for HIV testing or a follow-up clinic appoint-
ment, obviating the need to return to the clinic, thus
reducing patient’s transport costs and time spent on
clinic visits. Rationalization of the patient’s visit schedule
is important, because multiple visits to the clinics increase
the likelihood of pre-ART attrition [9,10].
Secondly, ST tubes improve the stability and integrity
of blood specimens, which is critical in the provision of
high-quality CD4 results. Delays in specimen transporta-
tion with standard Vacutainer EDTA tubes may lead to
spurious results due to the progressive decay of CD4
counts, especially at temperatures higher than 37°C [20].
Thirdly, ST tubes can simplify internal quality control
procedures. Daily quality control entails running “normal
blood samples” in conjunction with the commercial con-
trol beads, and laboratories usually rely on donors to ob-
tain normal samples; this may prove difficult owing to the
need to find a donor on a day-to-day basis. Normal blood
samples collected in CD4 STcan be stored for several days
and used multiple times for quality control purposes.
Despite the move towards initiating all patients who test
HIV positive on ART, regardless of their CD4+ T-cell
count, there is strong agreement among clinicians that a
baseline CD4 test will remain necessary to guide clinical
decisions about commencing prophylaxis and screening
for OIs [21]. Given that CD4 testing remains important in
ART programmes, it seems prudent that governments
and stakeholders continue to invest in sample transport
systems and strategies for the rapid delivery of laboratory
results (mHealth), which will not only benefit HIV pro-
grammes but the health system as a whole. Recently,
Kiyaga et al. [22] have shown the positive experience of
Uganda in the development of an effective sample trans-
port system to respond to the scale-up of early infant diag-
nosis (EID), the HUB system, whereby hubs feed into a
centralized coordinated national system, thereby increas-
ing efficiency and reducing costs and turnaround time of
results, not only for EID but also for other laboratory
services.
Table 3 Clinical agreement and misclassification rates between CD4 measured on EDTA Day 0 (reference test) and CD4
measured on ST Day 7 and Day 14 (index test) at CD4 thresholds for ART eligibility of 350 cells/μL and 500 cells/μL
EDTA Day 0 ST Day 7 Sensitivity: 100 (78.2 – 100); PPV: 100 (78.2 – 100)
≤350 ≥350 Total Specificity: 100 (89.7 – 100); NPV: 100 (89.7 – 100)
≤350 15 0 15 Total misclassification rate: 0
≥350 0 34 34 Upward misclassification rate: 0
Total 15 34 49 Downward misclassification rate: 0
EDTA Day 0 ST Day 14 Sensitivity: 83.3 (35.9 – 99.6); PPV: 100 (47.8 – 100)
≤350 ≥350 Total Specificity: 100 (75.3 – 100); NPV: 92.9 (66.1 – 99.8)
≤350 5 1 6 Total misclassification rate: 5.2
≥350 0 13 13 Upward misclassification rate: 5.2 (1/19)
Total 5 14 19 Downward misclassification rate: 0
EDTA Day 0 ST Day 7 Sensitivity: 100 (85.2 – 100); PPV: 88.5 (69.8 – 97.6)
≤500 ≥500 Total Specificity: 88.5 (69.8 – 97.6); NPV: 100 (85.2 – 100)
≤500 23 0 23 Total misclassification rate: 6.1 (3/49)
≥500 3 23 26 Upward misclassification rate: 0
Total 26 23 49 Downward misclassification rate: 6.1 (3/49)
EDTA Day 0 ST Day 14 Sensitivity: 88.9 (51.8 – 99.7); PPV: 80.0 (44.4 – 97.5)
≤500 ≥500 Total Specificity: 80.0 (44.4 – 97.5): NPV: 88.9 (51.8 – 99.7)
≤500 8 1 9 Total misclassification rate: 15.7 (3/19)
≥500 2 8 10 Upward misclassification rate: 5.2 (1/19)
Total 10 9 19 Downward misclassification rate: 10.5 (2/19)
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Although POC tests such as the Alere Pima CD4 have
been shown to be an important intervention to improve
retention in care prior to treatment initiation [11], costs
may hamper its widespread implementation in the lowest-
resource settings [12]. Experience from implementers in-
dicate that the introduction of POC technologies require
substantial human and financial resources for ongoing
training, supervision, data management, quality assurance,
instrument maintenance and supply control [23-25].
CD4 ST are more expensive than standard EDTA
tubes ($0.7 per 4 ml tube and $0.4 per 2 ml tube, com-
pared to $0.11 for standard 4 ml EDTA Vacutainer
tubes). The higher cost of CD4 ST may serve as a deter-
rent to adoption of this technology.
Our study has several strengths; it was carried out
under real-world, programmatic conditions, and samples
were collected and transported from rural clinics to a
central laboratory.
Some limitations in this study need to be acknowledged.
Firstly, experiments were carried out in December during
the rainy season so we were unable to assess the stability
of blood samples at higher temperatures. Secondly, as the
number of ST samples tested on Day 14 was relatively
small (n =19), the results need to be interpreted with cau-
tion. And thirdly, most of the participants recruited for
this study were having CD4 testing for monitoring pur-
poses, rather than to assess their eligibility for ART, and
therefore they are not representative of patients having
CD4 testing to determine ART eligibility. This may limit
the generalisability of our findings concerning PPV and
NPV.
Our study confirms previous findings and provides
further evidence that CD4 STs can be used as an alterna-
tive to standard EDTA tubes in settings where testing
within 48 hours is not feasible. Results of this study may
stimulate further research to compare the cost of POC
CD4 technologies with improved sample transport sys-
tems coupled with use of STs and rapid reporting of re-
sults and the impact of different strategies on patient
outcomes.
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